Researchers in Spain have successfully eliminated advanced pancreatic cancer in animal models using a novel triple-drug therapy, marking a major potential shift in how the disease is treated.
BREAKING:
— Globe Eye News (@GlobeEyeNews) January 29, 2026
Spanish scientists developed treatment that completely eliminates pancreatic cancer in laboratory mice. pic.twitter.com/hVhGFOlspD
A Spanish research team at the National Cancer Research Centre (CNIO) has developed a triple-drug therapy that completely eliminated aggressive pancreatic tumours in laboratory mice. Led by renowned scientist Mariano Barbacid, the six-year study reported no cancer recurrence and minimal side effects. This milestone offers a significant glimmer of hope against a disease notorious for its resistance to conventional medicine.
The innovative treatment targets multiple survival pathways simultaneously to prevent cancer cells from adapting. Barbacid, who identified the first human oncogene in the 1980s, has long argued that “only coordinated inhibition of multiple pathways can produce lasting responses.” By shutting down these mechanisms, the therapy effectively bypasses the rewiring process that typically leads to treatment failure in pancreatic ductal adenocarcinoma.
While public excitement grows, experts emphasize that human trials are the necessary next step. Independent reviewers in the journal PNAS highlighted the “unusually low toxicity” and durability of the results. As the team moves toward safety testing, this research provides one of the strongest indications that this deadly malignancy may finally be vulnerable to targeted, multi-drug combination therapies.